z-logo
Premium
Fatal Cardiac and Renal Allograft Rejection With Lenalidomide Therapy for Light‐Chain Amyloidosis
Author(s) -
Meyers D. E.,
AduGyamfi B.,
Segura A. M.,
Buja L. M.,
Mallidi H. R.,
Frazier O. H.,
Rice L.
Publication year - 2013
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/ajt.12391
Subject(s) - medicine , lenalidomide , bortezomib , amyloidosis , dexamethasone , immunoglobulin light chain , kidney , multiple myeloma , urology , immunology , antibody
We describe a patient who underwent a successful heart and kidney transplant for light‐chain amyloidosis. She had an excellent hematologic response to bortezomib/dexamethasone therapy. Follow‐up therapy with lenalidomide was started, and the patient quickly had a fatal allograft rejection of the heart and kidney. We present evidence to support the theory that lenalidomide, a known immunomodulator, may have stimulated the immune system and precipitated the fatal rejection episode.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here